Latest Amgen News & Updates

See the latest news and media coverage for Amgen. We track all announcements, press releases, and industry mentions in real time, all in one place.

Amgen

Multinational biopharmaceutical company

amgen.com

Headquarters: Thousand Oaks, United States
Founded year: 1980
Company type: Public company
Number of employees: 40,000+

Last updated Today

Latest news about Amgen

In short: Amgen expanded its obesity pipeline and secured European approval for Imdylltra while facing FDA scrutiny over data integrity for its drug Tavneos.

Company announcements

June 7 Amgen

Amgen presents new cardiometabolic data at ADA 2026

Repatha reduced cardiovascular events by 29% in high-risk diabetes patients. Real-world data highlight treatment gaps.

June 3 Amgen

Amgen to present new data at EULAR 2026

New Phase 3 data on UPLIZNA and real-world evidence on TAVNEOS support long-term safety and efficacy.

June 1 Amgen

Amgen's Imdylltra approved in Europe for SCLC

Approval based on Phase 3 trial showing 40% reduction in risk of death compared to chemotherapy.

May 19 Amgen

Amgen announces CFO Peter Griffith's retirement

Thomas Dittrich will return as CFO effective September 1, 2026; Griffith will remain through January 2027 to support a seamless transition.

Media coverage

Yesterday Yahoo Finance

Willful Patent Infringement Verdict Might Change The Case For Investing In Amgen (AMGN)

In June 2026, a Delaware jury ruled that Amgen and its subsidiary Teneobio willfully infringed Harbour BioMed's Grosveld patent, awarding Harbour US$20,203,704 in damages with...

June 14 Yahoo Finance

Amgen Faces Dual Turning Point With IMDYLLTRA Gain And Tavneos Risk

European Commission approves Amgen's IMDYLLTRA for extensive stage small cell lung cancer, opening a new targeted immunotherapy option for patients in the region. FDA proposes...

June 12 The Globe and Mail

Amgen's MARITIME-SWITCH Trial Targets GLP-1 Switchers in the Growing Obesity Drug Market

Amgen's new Phase 3 MARITIME-SWITCH trial looks at adults with obesity or overweight who move from older GLP-1 drugs to Amgen's next‑gen shot, maridebart cafraglutide...

June 12 Seeking Alpha

CMS proposes making Medicare drug price negotiations permanent

CMS proposes permanent Medicare drug price negotiation rules, selecting up to 20 Part D/Part B drugs for 2029 and beyond.

Never miss news about Amgen

Track Amgen and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Amgen competitors & trending companies

Browse news for competitors to Amgen and other trending companies.